secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lyell Immunopharma, Inc. (LYEL)
CIK:        0001806952
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0001628280-23-037346
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lyell Immunopharma Q3 net loss $50.9M; workforce cut 25%; cash runway to 2027
-----------------------------------------------------------------------------

- Net loss $50.9M vs $70.3M YoY; non-GAAP net loss $43.0M (flat YoY).
- Cash, equivalents and securities $598.2M; company expects funding operations into 2027.
- Workforce reduction ~25%; CMO Tina Albertson departing; focus on clinical candidates LYL797 and LYL845.
- Initial clinical data for LYL797 in 1H2024; LYL845 data in 2024; LYL119 IND expected 1H2024.
- R&D expenses $43.8M (+5% YoY); G&A $15.5M (-41% YoY); no revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1806952/000162828023037346/0001628280-23-037346-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1806952/000162828023037346/lyel-20231107.htm
  HTML page:      https://secwatch.observer/filing/0001628280-23-037346

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer